Brief: Bavarian Nordic Receives European Commission Approval Of Mpox/Smallpox Vaccine For Children Aged 2 To 12
07/08/2026 07:05
BRIEF-Bavarian Nordic Receives European Commission Approval Of Mpox/Smallpox Vaccine For Children Aged 2 To 12 Aug 7 (Reuters) - Bavarian Nordic A/S BAVA.CO:
BAVARIAN NORDIC RECEIVES EUROPEAN COMMISSION APPROVAL OF MPOX/SMALLPOX VACCINE FOR CHILDREN AGED 2 TO LESS THAN 12 YEARS
Source text: ID:nGNXX35xL
Further company coverage: BAVA.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Completes First Tranche Of Share Buy-Back Program
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
Brief: Bavarian Nordic Awarded Multi-Year Vaccine Contract By UK Government
Bavarian Nordic donates 75,000 mpox vaccine doses to global emergency stockpile
Brief: Bavarian Nordic Donates To Global Mpox Emergency Stockpile